In patients with an estimated creatinine clearance between 60 and 89 ml per minute preoperatively the risk of chronic kidney disease (creatinine clearance less than 60 ml per minute) after nephrectomy and partial nephrectomy was 58% and 15%,
respectively (p <0.001). In patients undergoing nephrectomy age and weight GSK690693 order were independent predictors of decreased creatinine clearance. A predictive model based on age and weight was highly accurate when applied to an external population (R = 0.757). A model for predicting renal function after partial nephrectomy based on age and tumor size was highly accurate in the external population (R = 0.848). A Web based tool was developed to estimate current and predict postoperative creatinine clearance (http://www.roswellpark.org/Patient_Care/Specialized_Services/Renal_Function_Estimator).
Conclusions:
The Cockcroft-Gault model based on actual weight is 1 of 5 models that accurately estimates renal function in patients with a kidney tumor. Models were developed and externally validated to predict renal function following nephrectomy.”
“Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiological functions. Pathological find more conditions leading to changes in their biophysical properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states. It is believed that changes in VGCC properties under pain-inducing conditions may play a causal APR-246 role in the development of chronic pain, including nerve injury-induced pain or neuropathic pain. For the past several decades, preclinical and clinical research in developing VGCC blockers or modulators for chronic pain management
has been fruitful, leading to some U. S. Food and Drug Administration-approved drugs currently available for chronic pain management. However, their efficacy in pain relief is limited in some patients, and their long-term use is limited by their side-effect profiles. Certainly, there is room for improvement in developing more subtype-specific VGCC blockers or modulators for chronic pain conditions. In this review, we summarized the most recent preclinical and clinical studies related to chronic pain medications acting on the VGCC. We also included clinical trials aiming to expand the application of approved VGCC drugs to different pain states derived from various pathological conditions, as well as drug combination therapies trying to improve the efficacies and side-effect profiles of current pain medications.”
“Purpose: Treatment options in patients with renal cell carcinoma have changed in recent years. However, few studies include detailed information on patient, clinical and health system characteristics in the evaluation of surgical management and the use of systemic therapies in community practice.